Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics

Ophthalmic Research

Volumn 37, Issue 3, 2005, Pages 117-122

  Kaliamurthy, J ^a   Nelson Jesudasan, C A ^a   Geraldine, P ^a   Parmar, P ^a   Kalavathy, C M ^a   Thomas, P A ^a,b  

^a BHARATHIDASAN UNIVERSITY   (India)

^b JOSEPH EYE HOSPITAL   (India)

Author keywords

Antibiotic; Bacterial infection; Gatifloxacin; In vitro susceptibility; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; NEOMYCIN; NORFLOXACIN; OFLOXACIN; TETRACYCLINE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS, LOCAL; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS;

EID: 22544450491     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084270     Document Type: Article

References (31)

1. Seal DV, Bron AJ, Hay J: Ocular Infection. Investigation and Treatment in Practice. London, Martin Dunitz, 1998, pp 1-269.
2. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P: Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the bacterial keratitis study group. Arch Ophthalmol 1995;113:1257-1265.
3. Jones RN, Beach ML, Pfaller MA, Doem GV: Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America. Diagn Microbiol Infect Dis 1998;32:247-252.
4. Tsurumaki Y, Manda H, Takei M, Hosaka M: In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan. J Antimicrob Chemother 2000;45:685-689.
5. Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro M, Tenover FC: Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2000;44:2962-2968.
6. Jones RN, Biedenbach DJ, Erwin ME, Beach ML, Pfaller MA, The Quality Control Study Group: Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. J Clin Microbiol 1999;37:1999-2002.
7. Mather R, Karenchak LM, Romanowski EG, Kowalski RP: Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-466.
8. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ: Gatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-505.
9. Barrow GI, Feltham RKA: Cowan and Steel's Manual for the Identification of Medical Bacteria, ed 3. Cambridge, Cambridge University Press, 1993.
10. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7. National Committee for Clinical Laboratory Standards, Wayne, 2000.
11. Kirkwood BR: Essentials of Medical Statistics. Osney Mead, Blackwell Scientific Publications, 1988.
12. Egger SF, Ruckhofer J, Alzner E, Hell M, Hitzl W, Huber-Spitzy V, Grabner G: In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res 2001;33:117-120.
13. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, ed 5. National Committee for Clinical Laboratory Standards, Wayne, 2000.
14. Wilhelmus KR, Hyndiuk RA, Caldwell DR, Abshire RL, Folkens AT, Godio LB: 0.3% Ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch Ophthalmol 1993;111:1210-1218.
15. Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, Badrinath SS, Reddy MK, Adenis JP, Klauss V: Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology 1996;103:1854-1863.
16. Garg P, Sharma S, Rao GN: Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999;106:1319-1323.
17. Cheung J, Slomovic AR: Microbial etiology and predisposing factors among patients hospitalized for corneal ulceration. Can J Ophthalmol 1995;30:251-255.
18. Wong T, Ormonde S, Gamble G, McGhee CN: Severe infective keratitis leading to hospital admission in New Zealand. Br J Ophthalmol 2003;87:1103-1108.
19. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y: Bacterial keratitis: A prospective clinical and microbiological study. Br J Ophthalmol 2001;85:842-847.
20. Varaprasathan G, Miller K, Lietman T, Whitcher JP, Cevallos V, Okumoto M, Margolis TP, Yinghui M, Cunningham ET Jr: Trends in the etiology of infectious corneal ulcers at the F.I. Proctor Foundation. Cornea 2004;23: 360-364.
21. Carmichael TR, Wolpert M, Koornhof HJ: Corneal ulceration at an urban African hospital. Br J Ophthalmol 1985;69:920-926.
22. Williams G, Billson F, Husain R, Howlader SA, Islam N, McClellan K: Microbiological diagnosis of suppurative keratitis in Bangladesh. Br J Ophthalmol 1987;71:315-321.
23. Al-Hazzaa SA, Tabbara KF: Bacterial keratitis after penetrating keratoplasty. Ophthalmology 1988;95:1504-1508.
24. Upadhyay MP, Karmacharya PC, Koirala S, Tuladhar NR, Bryan LE, Smolin G, Whitcher JP: Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am J Ophthalmol 1991;111:92-99.
25. Srinivasan M, Gonzales CA, George C, Cevallos V, Mascarenhas JM, Asokan B, Wilkins J, Smolin G, Whitcher JP: Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol 1997;81:965-971.
26. Aasuri MK, Reddy MK, Sharma S, Rao GN: Co-occurrence of pneumococcal keratitis and dacryocystitis. Cornea 1999;18:273-276.
27. Everett SL, Kowalski RP, Karenchak LM, Landsittel D, Day R, Gordon YJ: An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea 1995;14:382-387.
28. Fukuda H., Hori S, Hiramatsu K: Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother 1998;42:1917-1922.
29. Kunimoto DY, Das T, Sharma S, Jalali S, Majji AB, Gopinathan U, Athmanathan S, Rao TN: Microbiologic spectrum and susceptibility of isolates. I. Postoperative endophthalmiitis. The Endophthalmitis Research Group. Am J Ophthalmol 1999;128:240-242.
30. Kunimoto DY, Das T, Sharma S, Jalali S, Majji AB, Gopinathan U, Athmanathan S, Nagaraja Rao T: Microbiologic spectrum and susceptibility of isolates. Part II. Posttraumatic endophthalmiitis. The Endophthalmitis Research Group. Am J Ophthalmol 1999;128:242-244.
31. Chalita MR, Hofling-Lima AL, Paranhos A Jr, Schor P, Belfort R Jr: Shifting trends in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004;137:43-51.